lunes, 11 de febrero de 2013

Knowledge integration in ca... [Cancer Epidemiol Biomarkers Prev. 2013] - PubMed - NCBI

Knowledge integration in ca... [Cancer Epidemiol Biomarkers Prev. 2013] - PubMed - NCBI


Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):3-10. doi: 10.1158/1055-9965.EPI-12-1144. Epub 2012 Oct 23.


Knowledge integration in cancer: current landscape and future prospects.





Source


Corresponding Author: John P.A. Ioannidis, Stanford Prevention Research Center, 1265 Welch Rd, MSOB X306, Stanford University School of Medicine, Stanford, CA 94305. jioannid@stanford.edu.



Abstract



Knowledge integration includes knowledge management, synthesis, and translation processes. It aims to maximize the use of collected scientific information and accelerate translation of discoveries into individual and population health benefits. Accumulated evidence in cancer epidemiology constitutes a large share of the 2.7 million articles on cancer in PubMed. We examine the landscape of knowledge integration in cancer epidemiology. Past approaches have mostly used retrospective efforts of knowledge management and traditional systematic reviews and meta-analyses. Systematic searches identify 2,332 meta-analyses, about half of which are on genetics and epigenetics. Meta-analyses represent 1:89-1:1162 of published articles in various cancer subfields. Recently, there are more collaborative meta-analyses with individual-level data, including those with prospective collection of measurements [e.g., genotypes in genome-wide association studies (GWAS)]; this may help increase the reliability of inferences in the field. However, most meta-analyses are still done retrospectively with published information. There is also a flurry of candidate gene meta-analyses with spuriously prevalent "positive" results. Prospective design of large research agendas, registration of datasets, and public availability of data and analyses may improve our ability to identify knowledge gaps, maximize and accelerate translational progress or-at a minimum-recognize dead ends in a more timely fashion. Cancer Epidemiol Biomarkers Prev; 22(1); 3-10. ©2012 AACR.



PMID:

23093546
[PubMed - in process]

No hay comentarios:

Publicar un comentario